Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Constellation Healthcare Technologies beefs up board

Dr Zimberg was one of the founding partners of a biotech-focused merchant bank
Constellation Healthcare Technologies beefs up board
Dr Zimberg is a highly-respected radiation oncology specialist

US-based healthcare services provider Constellation Healthcare Technologies (LON:CHT) has appointed highly respected physician Dr Shawn Zimberg to the board as a non-executive director.

Dr Zimberg is the medical director of Advanced Radiation Centers of New York, a division of Integrated Medical Professionals, and has served on the board of Integrated Medical Professionals since July 2006.

Constellation said he is a leading expert in the field or radiation oncology. He was also one of the founding partners of Evolution Partners, a merchant and investment bank focused on life sciences, biotechnology and healthcare & wellness industries.

"He is a highly respected physician and entrepreneur. His addition will help us greatly as we pursue our strategy of being one of the leading healthcare services and technology businesses in the US,” said Paul Parmar, chief executive officer of Constellation.

“Constellation will benefit from his medical insight, especially in the billing and practice management verticals of our business. Constellation will also gain from Dr Zimberg's broader knowledge of the US healthcare sector, its pressure points and how the company can optimise its positioning in-front of the medical community, " Parmar added.

View full CHT profile View Profile

Constellation Healthcare Technologies, Inc. Timeline

Related Articles

ventripoint_device.png
June 21 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use